Global Polymyalgia Rheumatica Market Overview: Trends Shaping Growth to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Polymyalgia Rheumatica Industry Expected To Reach By 2029, Starting From 2025 Levels?

The market for polymyalgia rheumatica has experienced substantial growth in recent years. It is anticipated to increase from $1.28 billion in 2024 to $1.36 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.9%. This historical growth can be attributed to heightened awareness among healthcare providers, the increasing adoption of corticosteroids, the expansion of specialty clinics, the introduction of biologic therapies, and rising healthcare budgets.

The polymyalgia rheumatica market is projected to experience significant expansion over the next few years, with its size anticipated to reach $1.72 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.1%. This growth during the forecast period is primarily fueled by increasing adoption of biologics, the expanding field of precision medicine, accelerated drug approvals, broader reimbursement policies, and an increase in clinical trials. Furthermore, major trends anticipated in this period include the development of combination therapies, advancements in personalized medicine, continued evolution of precision medicine, the integration of electronic health records, and breakthroughs in biomarkers.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

Which Drivers Are Supporting Growth Of The Polymyalgia Rheumatica Market?

The expanding need for personalized medicine is anticipated to drive the future expansion of the polymyalgia rheumatica market. This approach involves medical care customized to an individual’s unique genetic makeup, way of life, and particular health status, aiming for superior results. The impetus for personalized medicine stems from progress in genetic studies, increasing patient desires for customized therapies, and enhancements in diagnostic tools. Genetic research has deepened our comprehension of individual genetic differences, facilitating more bespoke treatments that target particular genetic markers. It aids in choosing medications most likely to be effective given a patient’s traits, resulting in a safer and more impactful treatment strategy. As an illustration, in February 2024, data from the Personalised Medicine Coalition, a US-based hospital and health care entity, revealed that in 2023, the Food and Drug Administration cleared 16 new personalized therapies for rare disease patients, an increase from six in 2022. Consequently, the emergence of personalized medicine is a key factor propelling the expansion of the polymyalgia rheumatica market.

What Are The Leading Segments Analyzed In The Polymyalgia Rheumatica Market?

The polymyalgia rheumaticamarket covered in this report is segmented –

1) By Treatment: Corticosteroids; Nonsteroidal Anti-Inflammatory Drugs; Disease-Modifying Antirheumatic Drugs; Biologics

2) By Route Of Administration: Oral; Intravenous; Subcutaneous

3) By Patient Type: Adult; Geriatric; Periatric

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone; Methylprednisolone; Hydrocortisone; Dexamethasone

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Aspirin; Celecoxib

3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate; Leflunomide; Sulfasalazine; Hydroxychloroquine

4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-6 (IL-6) Inhibitors; B-Cell Inhibitors; Janus Kinase (JAK) Inhibitors

What Long-Term Trends Will Shape The Future Growth Of The Polymyalgia Rheumatica Industry?

Companies prominent in the polymyalgia rheumatica market are prioritizing the development of advanced medications, such as interleukin-6 (IL-6) receptor blockers, to offer more targeted and effective treatment options. Interleukin-6 (IL-6) receptor blockers are biological drugs that work by inhibiting IL-6, a key pro-inflammatory cytokine in autoimmune diseases. By blocking IL-6, these therapies reduce inflammation and alleviate symptoms, thereby improving the quality of life for PMR patients. As an illustration, in February 2023, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, and Sanofi, a France-based healthcare company, announced that the Food and Drug Administration (FDA) had approved Kevzara (sarilumab) for treating polymyalgia rheumatica (PMR) in adults who either did not respond adequately to corticosteroids or could not tolerate their tapering. Kevzara, which is the first and only biologic approved for this condition, operates by inhibiting IL-6-mediated signaling. This approval was granted based on a study where 28.3% of patients on sarilumab achieved sustained remission at week 52, compared to 10.3% of those on placebo. Kevzara is administered via subcutaneous injection once every two weeks and is also approved for treating moderately to severely active rheumatoid arthritis. Sanofi’s stock (SNY) is currently valued at $54.13 on the NASDAQ.

Which Leading Companies Dominate The Polymyalgia Rheumatica Market Share?

Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford HealthCare, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women’s Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Polymyalgia Rheumatica Market?

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Polymyalgia Rheumatica Market Report:

https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp

Browse Through More Reports Similar to the Global Polymyalgia Rheumatica Market 2025, By The Business Research Company

Bipolar Disorder Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

Hpv Associated Disorders Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hpv-associated-disorders-global-market-report

Bleeding Disorders Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795